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Abstract  
The regulation of plasmin generation on cell surfaces is of critical importance in the control of 
vascular homeostasis. Cell-derived microparticles participate in the dissemination of 
biological activities. However their capacity to promote plasmin generation has not been 
documented. In this study, we show that endothelial microparticles (EMP) from TNFα-
stimulated endothelial cells, served as a surface for the generation of plasmin. The generation 
of plasmin involved expression of urokinase-type plasminogen activator (uPA) and its 
receptor (uPAR) at the surface of EMP and was further increased by their ability to bind 
exogenous uPA on uPAR. Plasminogen was activated at the surface of EMP in a dose-
dependent, saturable and specific manner as indicated by the inhibition of plasmin formation 
by ε-amino-caproic acid (ε-ACA) and carboxypeptidase B. EMP-induced plasmin generation 
affects tube formation mediated by endothelial progenitor cells. However, low amounts of 
EMP increased tube formation whereas higher concentrations inhibited it. Prevention of these 
effects by inhibitors of either uPA or plasmin, underscore the key role of EMP-induced  
plasmin generation. In conclusion, we demonstrated that EMP act as vectors supporting 
efficient plasmin generation and dissemination, a new pathway in the regulation of endothelial 
proteolytic activities with potential involvement in inflammation, angiogenesis and 
atherosclerosis.  
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Introduction 
Microparticles are vesicles resulting from the blebbing of the cellular membrane of most 
activated or apoptotic cells.1 These microvesicles have been described in various cellular 
models and in different pathological conditions as reliable hallmarks of cell damage.2 Because 
they convey various bioactive effectors originating from the parent cells, microparticles (MP) 
may exhibit a spectrum of biological activities; they regulate endothelial or blood cells 
functions, participate in inflammatory responses or angiogenesis and propagate biological 
responses involved in haemostatic balance.3 We previously reported the capacity of 
endothelial cells to release microparticles after inflammatory stimulation, and the presence of 
increased levels of circulating endothelial microparticles (EMP) in patients with thrombotic 
disorders.4 Since this initial report, elevated levels of EMP have been documented in various 
pathological conditions including coronary syndromes5, renal failure6, diabetes7, 
antiphospholipid syndrome8, thrombotic thrombocytopenic purpura9 and sickle cell disease10, 
in which they reflect endothelial dysfunction and are associated with a poor clinical outcome.  
 EMP provide procoagulant phospholipid surfaces for the assembly and activation of 
coagulation factors, mainly through phosphatidylserine translocation to the exoplasmic leaflet 
as a result of membrane remodeling. Their involvement in thrombin generation also results 
from their capacity to harbor, deliver or induce tissue factor activity.11-13 However, a more 
complex contribution to the haemostatic balance is suggested by their expression of 
thrombomodulin, tissue factor pathway inhibitor and endothelial protein C receptor thus 
providing a possible antithrombotic counterbalance.14, 15  
Another key regulator of the vascular homeostasis is the plasminogen activation system. 
Plasminogen activation is mediated by two serine proteases: tissue-type plasminogen activator 
(t-PA), which is mainly implicated in fibrinolysis, and urokinase-type plasminogen activator 
(uPA), which is critically involved in pericellular proteolysis due to its high affinity cell 
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surface receptor uPAR.16 Plasmin generation induced by uPA and subsequent activation of 
matrix metalloproteinases (MMP) promotes cell migration through interstitial matrix and 
participates in processes such as tissue remodeling, cancer invasion and angiogenesis.17-19 
Importantly, we have shown that uncontrolled plasminogen activation can have deleterious 
consequences by inducing cell detachment and apoptosis.20, 21 The regulation of plasmin 
generation at the endothelial surface is therefore of critical importance in the control of 
vascular homeostasis. 
Because MP convey protein and functional systems expressed by the parent cell, we 
hypothesized that EMP may serve as active surfaces for interaction with plasminogen and 
plasmin formation, a hitherto undescribed function. The objective of this study was therefore 
to analyze the capacity of EMP to bind and convert plasminogen into active plasmin and to 
define the impact of plasmin generation on EMP capacity to regulate angiogenic responses 
mediated by endothelial progenitor cells (EPC) in vitro. 
 
 
Materials and Methods 
Preparation of plasminogen and plasminogen-free fetal calf serum.  
Plasminogen was purified by lysine-affinity chromatography and molecular sieving as 
reported previously.22 Plasminogen-free fetal calf serum (FCS) was obtained by three cycles 
affinity adsorption on lysine-Sepharose (4 FCS vol/1 gel vol) and was subsequently checked 
and found to contain less than 0.1 nM plasmin(ogen) activity. 
 
Cell culture 
The human microvascular endothelial cell line (HMEC-1), obtained from Dr. Ades23  (Centers 
for Disease Control, Atlanta, GA, USA), was cultured in MCDB 131 medium (Invitrogen Life 
Technologies, Cergy Pontoise, France) supplemented with 10% MP-free FCS, 10 ng/ml 
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human recombinant epithermal growth factor (Upstate Cell Signaling Solutions, Lake Placid, 
NY, USA) and 1 µg/ml hydrocortisone (Sigma, St Quentin Fallavier, France). Human vein 
endothelial cells (HUVEC) were obtained by collagenase digestion as previously described24, 
cultured into 0,2 % gelatin coated flasks in EGM2 medium and  used at passage 2. Human 
saphenous vein endothelial cells were purchased from Clonetics (Grand Island, NY, USA) 
and cultured into 0,2 % gelatin coated flasks in EGM2-MV medium and  used at passage 6. 
 
Generation, harvesting and flow cytometry enumeration of EMP  
For most experiments, EMP were from HMEC-1 origin as this cell line is well characterized 
and considered representative of the microcirculation, the core of the vascular tree.23,25 EMP 
were purified from culture medium conditioned by sub-confluent HMEC-1 stimulated  for 48 
hours with 100 ng/ml TNF-α  (PeproTech Inc, Rocky Hill, NJ, USA) as previously described, 
with minor modifications.4 Culture supernatants from flasks were collected and cleared from 
detached cells or large cell fragments by centrifugation at 4300g for 5 minutes. The 
supernatants were then centrifuged at 20000g for 120 minutes at 4°C. Pelleted EMPs were 
washed 2 times and re-suspended in phosphate-buffered saline (PBS). The absence of residual 
TNF-α in this EMP samples was verified using an ELISA assay (R&D system, Minneapolis, 
MN, USA). Aliquots of 10 µl EMP suspension, 1/100 diluted, were labeled using fluorescein 
isothiocyanate (FITC)-conjugated annexin V (Abcys, Paris, France) and EMP were 
enumerated by flow cytometry as previously described.26 The same protocol was used to 
obtain EMP from quiescent HMEC-1, saphenous endothelial cells and endothelial progenitor-
derived cells (EPDC). 
 
H
AL author m
anuscript    inserm
-00160595, version 1
 6
Isolation and culture of endothelial progenitor cells from cord blood 
Human umbilical cord blood samples (30-50 ml) were collected from donors, in compliance 
with French legislation, in a sterile tube containing heparin (200 UI/ml). Mononuclear cells 
(MNC) were isolated by density gradient centrifugation. Briefly, blood was diluted 1:1 in 
phosphate-buffered saline containing 2 mM ethylenediaminetetraacetic (PBS/EDTA) and 
layered over lymphocyte separation medium (Eurobio, Les Ulis, France). After a 30 min 
centrifugation at 400g, MNC were washed three times in PBS/EDTA. Cord blood MNC were 
pre-plated in RPMI/10% FCS for 24 hours in plastic flasks. Non-adherent cells were plated 
onto 0.2% gelatin-coated 24-well plates (5.106 cells per well) and maintained in endothelial 
basal medium-2 (EBM-2) supplemented with EGM-2 SingleQuots (EGM-2 medium, 
Clonetics, Walkersville, MD, USA). The medium was changed every 4 days. The appearance 
of well-circumscribed colonies with a cobblestone morphology was monitored daily. For 
expansion of EPDC, colonies were trypsinized and cells were replated on a 6 wells plate 
(passage 1). Subsequently, confluent cells were trypsinized and re-plated in T75 flasks for 
further passages. Cells were maintained under standard conditions (humidified atmosphere, 
5% CO2, 37°C). 
 
Progenitor endothelial cell tube formation in Matrigel  
Flat-bottom 96-well plates were pre-coated with 1:1 mixture of cold Matrigel Basement 
Membrane (10 mg/ml, BD Biosciences, Bedford, MA, USA) and RMPI-10% FCS medium. 
After 45 minutes of polymerization at 37°C, EPDC were plated at 2.105 cells/well in 
RPMI/10% FCS with increasing concentrations of EMP from TNF-α-stimulated HMEC-1 or 
an identical volume of the supernatant from the last EMP washing. To test the role of FCS 
plasminogen in this system, native FCS was replaced by plasminogen-free FCS supplemented 
or not with 1 µM human plasminogen. For inhibition experiments, EMP were pre-incubated 
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with either an anti-uPA antibody (394O, American Diagnostica, Greenwich, CT, USA, 25 
µg/ml) or an irrelevant control IgG1 (25 µg/ml) or with serine-protease inhibitors (aprotinine, 
100 k.u.i./ml or α2-antiplasmin, 1 µM). After 24 hours, capillary tube formation was 
evaluated by measuring the number of polygons formed in a well under an inverted light 
microscope (Olympus) at 400x magnification. This time point has been chosen following 
previous kinetics experiments indicating that it is optimum to analyze tube formation in the 
presence of EMP. All experiments were performed in triplicate. 
 
EMP immobilization 
A physico-chemical adsorption principle was used to immobilize negatively charged EMP on 
a polycation surface. For that purpose, round-bottom PVC plates were activated with 25 
µg/ml poly-L-lysine and various concentrations of EMP in PBS were then incubated over 
night at 4°C with the activated surface. The plate was then washed and the immobilized EMP 
were tested as indicated. 
 
Plasmin generation test 
In round-bottom 96-well PVC plates, various concentrations of EMP, either in suspension in 
PBS supplemented with 0.8% bovine serum albumin (PBSA) or immobilised on poly-L-
lysine coated plates, were incubated with 50 µl of 1 µM plasminogen and 0.75 mM of a 
chromogenic substrate selective for plasmin (methyl-malonyl)-hydroxypropylarginine-p-
nitroanilide (CBS0065, Stago, Asnière, France). An identical volume of supernatant from the 
last EMP washing was used as control. In order to determine the Michaëlis constant of 
plasmin generation by EMP, a fixed number (2.105) of EMP and varying concentrations of 
plasminogen (0 to 5 µM) were used. Kinetics of plasmin generation were followed during 9h 
in a multiwell plate counter (MX5000, Dynex) at 37°C by measuring the change in 
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absorbance at 405 nm produced by the release of p-nitroaniline. In the case of activation 
experiments performed on immobilized EMP, the plate was washed with PBSA to eliminate 
unbound reactants and the plasmin bound to the immobilized EMP was detected by adding 50 
µl/well of 0.75 mM CBS0065 and measuring the change in absorbance at 405 nm. When 
indicated, the following inhibitors were pre-incubated with the EMP: 1 µg/ml goat anti-human 
tPA (Biopool, Uppsala, Sweden), 50 µg/ml mouse anti-human uPA (394O), 50 µg/ml rabbit 
anti-αvβ3 ( gift of J.C.Lissitzky ), 100 µg/ml anti-α-enolase (gift of R. Lopez Alemany) and 
the respective irrelevant control IgGs (Biocytex, Marseille, France); the uPA inhibitor, 
amiloride, was used at 100 µM and carboxypeptidase B (CpB) at 50 µg/ml, final 
concentrations. In separate experiments, the inhibitors α2-antiplasmin, aprotinin and ε-amino-
caproic acid (ε-ACA) were added to the plasminogen activation solutions at 100 nM, 100 
k.i.u./ml and 0.1 M final concentrations, respectively.  
 
Characterisation of uPA and uPAR in cell and EMP extracts  
HMEC-1 and pelleted MP were lysed in 100 mmol/l Tris-HCl buffer pH 8.1, containing 0.5% 
Triton X-100 and supplemented with complete protease inhibitor mixture (Roche Diagnostic 
GmbH, Mannheim, Germany) except for zymography samples. Lysates were clarified and 
protein concentrations were determined using the BCA kit (Pierce, Rockford, IL, USA). uPA 
and uPAR total antigen levels were assayed by ELISA (894 and 893 IMUBIND® ELISA kits, 
American Diagnostica) according to the manufacturer’s instruction. The results were 
expressed as ng of uPA or uPAR per mg of total proteins. For zymography, protein extracts (5 
µg), molecular weight markers and purified scuPA were electrophoresed under non-reducing 
conditions in 10% SDS-polyacrylamide gel copolymerised with 1 mg/ml α-casein from 
bovine milk (Sigma) and 20 µg/ml human plasminogen. After electrophoresis, SDS was 
eluted from the gel by washing for 1 h in 2.5% Triton X-100 buffer. The gels were then 
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incubated for 40h at 37°C in 50 mmol/l Tris-HCl buffer, pH 8, containing 5 mmol/l CaCl2, 
138 mmol/l NaCl and 0.03% Brij 35. Zymograms were developed by staining with 
Coomassie Brillant Blue Dye and destained to reveal clear bands of casein lysis, indicative of 
enzymatic activity. Samples run on casein gels without plasminogen or gels incubated in lysis 
buffer supplemented with 1 mM amiloride (Sigma) served as controls of uPA activity. For 
Western-blot analysis, protein extracts and purified human uPAR (American Diagnostica, 
Greenwich, CT, USA) used as positive control (20 µg/lane), were separated under non-
reducing conditions by 8% SDS-polyacrylamide gel and electrotransferred onto a 
nitrocellulose membrane. After blocking, the membranes were incubated overnight at 4°C 
with rabbit anti-human uPAR (399R, American Diagnostica, 0.5 µg/ml) antibodies, followed 
by the horseradish peroxidase-conjugated secondary antibodies. Immunocomplexes were 
visualized with the Supersignal West Pico chemiluminescence kit (Pierce).  
 
Immunoelectron microscopy of EMPs 
For uPA/uPAR immunogold labeling of EMP, droplets of MP isolated from TNFα-stimulated 
HMEC-1 were applied to 300 mesh nickel Formvar-carbon-coated grids (Agar Scientific, 
Essex, England) for 10 min. Samples were immunolabeled with either anti-uPA (3689, 
American Diagnostica, 10 µg/ml) or anti-uPAR (3932, American Diagnostica, 10 µg/ml) 
antibodies for 1 hour, washed with PBS and then reacted with the 15 nm beads gold-labeled 
secondary antibody (BBInternational, Cardiff, UK) for 1 hour. Grids were rinsed and 
negatively stained with 0.3% phosphotungstic acid (pH 7) before observation with a JEOL 
1220 electron microscope. Specificity of immunolabeling was determined in comparison to 
results obtained with an irrelevant control antibody or with gold-labeled secondary antibody 
alone.  
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Flow cytometry for uPA and uPAR on EMP 
EMP (10 µl) were labeled with either anti-uPA (394O, 25 µg/ml) or anti-uPAR (3932, 25 
µg/ml) antibodies for 1h, then FITC-labeled secondary antibody was added and incubated for 
30 min before samples were analyzed on a Cytomics FC500* flow cytometer (Beckman 
Coulter, Fullerton, CA, USA). MP were analysed according to the FSC/SSC characteristic in  
a gate with the  upper limit defined by beads of  0.9  µm and the lower limit defined by 0.3 
µm. Specificity of labelling was determined in comparison to results obtained with an 
irrelevant control antibody or with the secondary antibody alone. 
 
 Binding of uPA to EMP 
A fixed concentration of EMP was immobilised on poly-L-lysine coated 96-well plates. 
Increasing concentrations (0 to 18.5 nM) of sc-uPA (a kind gift of Dr HR Lijnen, University 
of Leuven) were incubated during 1h at 37°C with the immobilized microparticles in the 
presence of 4 µg/ml of poly-L-lysine in order to eliminate non specific binding of sc-uPA to 
the poly-L-lysine surface. To verify the specificity of the binding, a fixed concentration of 
native sc-uPA (0.1 nM) was mixed  with a 10 molar excees (1 nM) of a recombinant inactive 
form “rsc-uPA Ile 159→Gly” (H.R. Lijnen, University of Leuven). The native sc-uPA, 
specifically bound to EMP, was detected by measuring plasmin generation as describe above. 
 
Statistical analysis 
Data are expressed as mean +/- standard deviation. Statistical analysis was performed with 
Prizm software (GraphPad Software Inc., San Diego, CA, USA) and with KaleidaGraph 
software (Synergy Software, Reading, PA, USA). Significant differences were determined 
using non parametric Mann-Whitney test. A p value less than 0.05 was considered significant. 
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Results 
EMP are able to activate plasminogen into plasmin.  
To investigate the ability of EMP to generate plasmin, the microparticles were incubated with 
plasminogen and a plasmin-selective chromogenic substrate. As shown in Fig. 1A, plasmin 
generation occurred as a function of time and was proportional to the number of EMP. At 106 
EMP/well the plasmin generation  rate was 47.6 ±1.1 A405nmx10-3/min, 53-fold higher than at 
103 EMP/well (0.9 ±0.3 A405nmx10-3/min) (Fig.1B). At identical EMP concentrations (2. 105 
/50 µl) comparable results were obtained using EMP derived from quiescent or TNFα-
stimulated HMEC-1. In contrast, the level of plasmin generated by EMP was shown to vary 
according to their endothelial cell origin (Table 1). Thus, a more pronounced activity was 
produced by HMEC-1-derived MP as compared to MP of macrovascular origin (saphenous 
vein, HUVEC) whereas intermediate values were obtained for EPDC-derived 
MP.Plasminogen incubated with EMP was activated in a dose-dependent, saturable and 
specific manner (Fig. 1C, Km = 0.122µM, Vmax= 25.2 A405nm/min.103). As expected, 
plasmin activity was completely blocked in the presence of α2-antiplasmin or aprotinin (Fig. 
1D).  
 
Plasminogen is activated by uPA at the surface of EMP 
Supernatants from EMP washing failed to generate plasmin, ruling out the contribution of 
soluble factors and suggesting that the activation of plasminogen was dependent on factors 
associated with the EMP surface. In order to test this hypothesis, plasminogen activation 
experiments were performed on immobilized microparticles. In this system, plasmin 
generation was a function of the number of immobilized EMP (Fig. 2A). Plasmin was already 
detected on immobilized EMP at a concentration of 25000 EMP/well and increased 
progressively in a dose-dependent manner. At the end of the activation experiments the 
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immobilized EMP were washed and bound plasmin was detected using a plasmin-selective 
chromogenic susbtrate. The amount of EMP-bound plasmin increased as a function of the 
number of immobilised EMP (Fig. 2B). Since some plasmin was released into the medium 
during its generation, the amount bound after washing was lower than the total amount of 
plasmin formed. 
 In parallel experiments using EMP in suspension, plasmin generation was inhibited by the 
lysine analogue ε-ACA suggesting a lysine-dependent mechanism for plasminogen binding 
and activation that was confirmed by abrogation of plasmin formation upon cleavage of C-
terminal lysine residues on EMP by CpB (Fig 1D). Among proteins bearing C-terminal lysine 
residues, α-enolase was identified as a major binding protein as indicated by 65 % inhibition 
of plasmin formation with the specific antibody 11G1 (Fig 1D). The integrin αvβ3 that may 
influence plasminogen activation, mainly through interactions with uPA/uPAR system, was 
shown not to be involved in plasmin generation by EMP as indicated by the absence of effect 
of a specific neutralizing antibody (Fig 1D).  
 
The uPA/uPAR complex is present on EMP 
The value determined for the apparent Km of plasminogen activation on EMP was within the 
range determined for the uPA/uPAR system on endothelial cells and a variety of other cell 
types.27, 28 The plasminogen activator conveyed by EMP was identified as uPA as indicated by 
the inhibition of plasmin generation  by  (i) amiloride, a specific inhibitor of uPA, and by (ii) 
an antibody specific for uPA (>95% inhibition) (Fig. 1D). By contrast, an antibody directed 
against tPA had no significant effect on  plasmin generation. The presence of uPA activity on 
EMP was further confirmed by a lytic band on casein zymography corresponding to the 
molecular mass of uPA (Fig. 2C) which was also absent in gels into which amiloride (1 mM) 
was incorporated  (data not shown). Comparison of the lytic bands from the EMP and the 
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parent cells, normalized for protein content, showed a 3-4 fold increased of uPA in the EMP 
(representative experiment in Fig. 2C).  Similarly, when uPA antigen in EMP and cells were 
measured by ELISA, a 3-fold increase in uPA was found in the EMP (23.9 +/- 12.6 versus 8.3 
+/- 3.17 ng uPA/mg protein respectively, p<0.05). UPAR was identified in EMP and cell 
lysates by Western-blot and was found to co-migrate with mammalian uPAR. As for uPA, the 
EMP had more uPAR than the cells when normalized for equivalent total protein 
concentrations, (Figure 2D). The uPAR antigen level measured by ELISA was 4-fold higher 
in the EMP than in the parent HMEC-1 (57.7 +/- 14.54 versus 4.4 +/- 1.17 ng/mg protein 
respectively, p<0.05). The presence of uPA or uPAR on the EMP surface was also analysed 
by flow cytometry (figure 3A and 3B). The shift of fluorescence histogram after specific 
labeling of EMP with uPA and uPAR antibody compared to the irrelevant staining confirmed 
the presence of uPA and uPAR at the EMP surface. 
EMP were also analyzed by electron microscopy. Negative staining of the pellet revealed 
intact irregular shaped EMP ranging from 100 to 500 nm in size. Molecules of uPA and uPAR 
were detected on the outer surface after immunogold labeling with specific antibodies (Figure 
3C). No labeling was observed in experiments using control antibodies.  
 
Binding of sc-uPA to EMP-uPAR 
Since the amount of uPAR measured by ELISA was higher on EMP than on cells, we tested 
the capacity of immobilized EMP to bind exogenous scuPA specifically. A range of 
concentrations of scuPA was incubated with the immobilized EMP, washed and then tested in 
a plasminogen activation assay. Figure 3D shows that scuPA binding was dose-dependent, 
saturable and specific, as indicated by the inhibition of the binding by a modified form of 
scuPA that resists activation (Fig 3D, insert). Analysis of raw data with the Langmuir 
equation for single-site binding allowed calculation of a very low dissociation constant (Kd = 
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0.1nM), indicating a very high affinity of scuPA for its EMP anchored receptor, in agreement 
with previous published data for the uPA/uPAR system.28 Since elution of intrinsic uPA could 
not be performed before the binding experiments these results indicate that the amount of uPA 
originally bound is relatively small compared with the high uPAR binding capacity of EMP.  
 
EMP affect tube formation by endothelial progenitor cells in vitro. 
EPC were supplemented with increasing amounts of EMP (2.103 to 8.105) and tube formation 
in Matrigel was evaluated using the supernatant from the last EMP washing as control (100% 
tube formation). As shown on figure 4A, a biphasic effect was observed: at low EMP 
concentrations (≤ 2.103/well), polygon number and tube formation increased by 20% over 
control (p= 0.012) whereas higher amounts of EMP (≥ 2.105 EMP/well) had the reverse 
effect. Thus, tube formation decreased progressively with the increase in the number of EMP 
reaching 55% decrease below control (p<0.001) at 8.105 EMP/well. Concomitant with the 
decrease in tube formation, morphologic cell changes were observed (rounded cells and 
retracted cell clusters) (fig 4B). The moderate pro-angiogenic effect of MP seems to be less 
potent as compared to VEGF (see Supplementary data and figure available on the Blood 
website). . 
 
Plasmin is involved in the EMP effects on tube formation  
An anti-uPA antibody and α2-antiplasmin were used to determine whether the observed 
effects of EMP on EPC tube formation were related to plasmin generation. As illustrated in 
Fig. 4C, in the presence of these inhibitors, EMP had no more effect on tube formation.  
We also considered the presence of plasmin in the Matrigel medium because the gel itself and 
the culture medium (RPMI/10% FCS) contain plasminogen29 and the EMP are a source of 
uPA. The plasmin chromogenic substrate was added with the EMP in Matrigel allowing 
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detection of increased plasmin generation from 105 EMP (p<0.001)
 
at 2h of incubation (Fig. 
5A). The contribution of FCS plasminogen to plasmin formation was estimated using 
plasminogen-free FCS (Fig 5B). Under these conditions plasmin generation was moderately 
reduced (-11.8%, p=0.0001) compared to native FCS and was not influenced by the amount 
of EMP added, suggesting the presence of a basal plasmin generation in the Matrigel. The 
addition of plasminogen to plasminogen-free FCS restored plasmin formation to the level 
observed with native FCS in the absence of EMP and was again importantly increased as a 
function of the number of added EMP (more than 75% increase at 2.105 EMP/well, Fig 5B). 
These data confirmed the role of Matrigel and plasminogen from FCS in plasmin generation 
in the absence of EMP, and the strong potential capacity of EMP to enhance plasmin 
generation.   
Altogether, these data indicate that the uPA/uPAR system of EMP is responsible for plasmin 
generation and that plasmin proteolytic activity is involved in the EMP effects on tube 
formation by EPC.  
 
 
Discussion 
The plasminogen activation system plays a pivotal role in maintaining vascular patency and 
facilitating cell migration and angiogenesis. Binding of plasminogen to fibrin or the cell 
surface is of critical importance to regulate and target the proteolytic activity. Although the 
presence of uPAR on endothelial microparticles has previously been described30, its 
functional consequences, to our knowledge, have not been investigated as yet. The present 
study is the first demonstration that EMP provide a catalytic surface for the conversion of 
plasminogen into plasmin by expressing uPA and uPAR. Plasmin generation was EMP 
surface-dependent and could be augmented by binding of exogenous uPA to EMP-uPAR. As 
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a result, EMP were shown to modulate the angiogenic responses of endothelial progenitors in 
vitro.  
The generation of plasmin at the EMP surface was supported by inhibition experiments using 
the lysine analog ε-ACA and CpB. The inhibitory effect of ε-ACA, which occupies the 
lysine-binding site of plasminogen kringles 1 and 4 indicated lysine-dependent binding of 
plasminogen to the activation surface. The inhibition of plasmin formation by CpB confirmed 
that plasminogen activation was dependent on its cell surface binding to C-terminal lysine 
residues. This mechanism was further confirmed by inhibition of plasmin generation with a 
monoclonal antibody directed against α-enolase, a major plasminogen binding protein on cell 
surfaces.31 Taken together, these data demonstrated that EMP bind plasminogen and provide a 
catalytic surface for plasmin generation. The kinetics of plasminogen activation by the EMP 
were similar to those described for cells expressing uPA and uPAR.27, 28, 32 Accordingly, 
ELISA and zymography experiments revealed that EMP express uPA and uPAR. Part of this 
uPA and uPAR expression was located on the EMP surface as evidenced by electron 
microscopy and flow cytometry.  
The major contribution of EMP-bound uPA to the plasmin generation was further 
demonstrated by the following observations (i) plasmin generation was blocked by the uPA 
inhibitor amiloride and by a uPA-neutralizing monoclonal antibody, (ii) tPA-dependent lytic 
activity was absent on  zymograms and neutralizing tPA antibodies did not affect plasmin 
generation.  
EMP were also shown to bind exogenous sc-uPA. Both, the affinity of sc-uPA binding and 
the competitive effect of a recombinant form of uPA (rsc-uPA Ile159→Gly), consistent with 
uPA/uPAR interaction, demonstrate that the EMP surface bears uPAR molecules devoid of 
uPA, allowing the specific binding of exogeneous uPA. These data, together with the 
expression of uPAR in excess of uPA, suggest that plasmin generation by EMP can be 
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amplified by uPA transferred from the local environment to the EMP surface. This 
mechanism may have implications in tumor angiogenesis where uPA secretion is promoted. 
Thus MP from tumor cells and EMP could participate in amplification of proteolytic 
processes.33 
Several reports have demonstrated that cell surface-bound plasmin is responsible for 
pericellular proteolysis and matrix degradation as compared to the soluble form.27, 34 This 
efficient activity results from protection against inactivation by physiological inhibitors, a 
direct contact with its matrix substrates, and the existence of amplification loops for 
plasminogen activation.16 Interestingly, plasmin once formed, remains partly bound to the 
EMP surface. Collectively, these data show that EMP act as vectors of efficient plasmin 
generation. 
This proteolytic activity is not the hallmark of cell activation by TNFα since it was similarly 
observed on EMP derived from quiescent endothelial cells. The substantial differences in 
plasmin generation observed among various endothelial cell types is consistent with the 
heterogeneous expression level of uPA/uPAR system along the vascular tree.35  
Vascular homeostasis is the result of an equilibrium between injury and capacity for repair.3 
Regeneration of damaged endothelium has been recently shown to involve not only 
angiogenesis but also vasculogenesis mediated by endothelial progenitors, both processes 
being largely dependent on proteolytic activities.35 Thus, the capacity of EMP to behave as 
vector of proteolytic activities raises the possibility that EMP may modulate EPC mediated 
repair processes. Consistently, apoptotic bodies from HUVEC have been shown to stimulate 
differentiation of endothelial progenitor, thereby representing a potential signaling pathway 
linking damaged cells to progenitors in the facilitation of the repair process.36 In our study, 
co-culture experiments showed that EMP affect EPC angiogenesis in Matrigel in a 
concentration dependent manner. While low amounts of EMP increased tube formation, 
H
AL author m
anuscript    inserm
-00160595, version 1
 18
higher concentrations inhibited it. This dual effect involved EMP associated plasmin since (i) 
in our co-culture model, EMP retained the capacity to increase plasmin concentration by 
activating the plasminogen of the culture medium and (ii) EMP effect was abrogated in the 
presence of α2-antiplasmin and a uPA-blocking antibody. The proangiogenic effect of EMP is 
consistent with plasmin associated proteolytic activity that favours cell migration via 
extracellular matrix processing and direct interaction with αvβ3 integrin19. The latter is, 
however, not involved in the process of plasmin generation (Fig 1D). Although this 
proangiogenic effect was observed with EMP present in a low number, plasmin was readily 
detected indicating that the local concentration of plasminogen was sufficient to ensure 
efficient plasmin generation. Other mechanisms may also be involved. MP from HUVEC 
stimulated with growth factors have been shown to stimulate angiogenic properties of mature 
endothelial cells and this effect was related to their content in matrix metalloproteinases.37 
Consistently, we observed an increase in MMP-2 and MMP-9 activities in condition media of 
Matrigel experiments in the presence of low dose of EMP (data not shown). Plasmin may also 
affect angiogenesis indirectly through activation of these MMPs.18  
In our study, high concentrations of EMP produced high amounts of plasmin and a dose-
dependent decrease in tube formation by EPC.  This inhibitory effect is in line with the role of 
an excessive plasmin generation leading to extracellular matrix degradation, alteration of cell 
anchorage and apoptosis.20, 38 Morphological changes in EPC co-cultured with high EMP 
amounts were indeed observed: accumulation of round and retracted cells evoking cell 
detachment, an effect that precedes apoptotic cell death.21 Protective and noxious effects of 
plasmin formation have also been observed in a cellular model of amyloid β degradation, 
suggesting that a similar effect may occur in vivo.39 Our data add to the observations of 
Mezentsev et al (2005) that reported a major contribution of oxidative stress in the 
impairment of angiogenic behaviour of mature endothelial cells.40 Although, in this study no 
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proangiogenic effect at low doses of EMP was observed, this discrepancy may be related to 
the specific properties of endothelial progenitors. EPC have been reported to display increased 
sensitivity to proangiogenic stimulation and reduced sensitivity to oxidative stress compared 
to mature endothelial cells.41 Hence, the magnitude of an MP angiogenic signal may be 
influenced not only by MP cellular origin and concentration but also by the nature of the 
target cells.   
In conclusion, we have identified cell-derived MP as new actors in the plasminogen activation 
system, an undescribed facet of the multiple biological processes involving EMP in the 
control of vascular homeostasis. The role of EMP-bound plasmin in pathological settings 
involving inflammation, atherosclerosis, angiogenesis and tumor growth, remains to be 
investigated. The high concentration of MP reported in atherosclerotic plaques suggests that 
EMP induced plasmin generation could participate in the modulation of cell apoptosis 
/angiogenesis balance influencing plaque vulnerability. In stroke, released EMP could be 
actors linking inflammation, cell damage and dysregulated repair processes.42  
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                             Table 1. Plasmin generation by endothelial microparticules 
 
 
 
HMEC-1: Human microvascular endothelial cell type 1. EPDC: Endothelial 
progenitor-derived cells. HUVEC: Human umbilical vein endothelial cells. 
 
EMP (2.105/well) derived from Plasmin generation (%, mean±SD) 
TNFα-stimulated HMEC-1 100  
Quiescent HMEC-1 98.0± 6.3 
EPDC 27.7 ±  5.5 
Saphenous vein endothelial cells 13.0 ±  2.6 
HUVEC 7.6 ±  3.3 
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Figure legends 
Figure 1. EMP are able to activate plasminogen into plasmin. (A) Plot of plasmin 
generated versus time at varying EMP amounts per 50 µl/well ( = 106 ;  = 105; 

 = 104; x 
= 103; + = control without EMP) and fixed final concentrations of plasminogen (1 µM) and a 
plasmin-selective chromogenic substrate (0.75 mM). Representative graph of four 
independent experiments. (B) Similar experiment as in A expressed as change in absorbance 
at 405 nm per minute versus EMP amount per well (S:  EMP last washing supernatant used as 
control). (C) Plasmin generated at varying plasminogen concentrations (0 to 5 µM) and a 
fixed amount (2.105/50 ul) of EMP was detected with a chromogenic substrate as in A. Raw 
data (

) were fitted to the Michaelis-Menten equation allowing calculation of non-specific 
activity () and a Km = 0.122 µM for specific plamin generation (). (D) Effect of various 
inhibitors on the generation of plasmin by EMP (2.105/50 µl) at 0.5 µM plasminogen (α2AP = 
α2-antiplasmin; ε-ACA = ε-amino-caproïc acid; CPB = Carboxypeptidase B; antibodies to 
uPA and tPA αvβ3 and α-enolase as compared to an isotype control IgG1) Results are the 
mean±SD of three independent experiments. 
 
Figure 2. Plasminogen is activated at the surface of EMP by uPA. (A & B) A variable 
number of EMP immobilised on poly-L-lysine surfaces were incubated with fixed 
concentrations of plasminogen (0.5 µM) and the plasmin-selective chromogenic substrate 
(0.75 mM). The graph in (A) shows an increase in the formation of plasmin as a function of 
the number of immobilised microparticles. Unbound reagents were then washed off and the 
chromogenic substrate added to detect plasmin that remained bound to the immobilized EMP; 
the graph (B) shows an increase in bound plasmin as a function of the number of immobilised 
EMP. Representative graphs (Mean±SD) of three independent experiments. (C & D) Protein 
extracts from HMEC-1 and its derived EMPs were processed for zymography (C) to detect 
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plasminogen activator activity (5 µg protein/lane; S: EMP last washing supernatant) and for 
immunoblot (D) using rabbit antibodies against uPAR and purified uPAR as reference (20 µg 
protein/lane). The ~50 kDa and upper bands in (C) were inhibited by antibodies to urokinase 
(not shown). A space has been inserted to indicate where a gel lane was cut.  These gels came 
from different experiments as indicated by the space between the gels. 
 
 Figure 3. Identification of uPA, uPAR and uPA/uPAR complex on EMP.  (A & B) 
Measured fluorescence intensity by flow cytometry analysis of EMP with anti-uPA (A) and 
anti-uPAR (B) antibodies (black) and the corresponding isotype controls (gray). (C) 
Representative images of immunogold labeling of uPA (top) and uPAR (bottom) analysis on 
EMP by transmission electron microscopy. The dimension of the bars indicate the relative 
small size of these EMP and the clusters of 15 nm gold particles (black dots) indicate the 
presence of uPA and uPAR at the surface of EMP. (D) Main graph: isotherm of the binding of 
varying amounts of scuPA incubated with EMP immobilized on a poly-L-lysine surface. The 
amount of bound scuPA was detected by its ability to activate plasminogen using a 
chromogenic substrate selective for plasmin. Data fitted to the Langmuir equation as indicated 
in Methods allowed calculation of a dissociation constant, Kd = 0.1 nM, for the interaction of 
scuPA with its receptor. Representative graph (Mean±SD) of three independent experiments. 
Inset: specificity of the binding of native scuPA is demonstrated by its inhibition with a 
modified recombinant form of scuPA (r-scuPA, ILe159Gly) that bind to its receptor but 
cannot be activated. The bars represent the mean±SD of three independent experiments. 
 
 
Figure 4. EMP affect the angiogenic properties of endothelial progenitors in vitro: 
effects on tube formation in Matrigel. EPDC in RPMI/10% FCS and varying amounts of 
EMP were plated on Matrigel and tube formation was evaluated after 24 h of incubation. (A) 
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Biphasic effect of EMP on tube formation: at low EMP concentrations (≤ 2.103/well), polygon 
number and tube formation increased by 20% (p= 0.012, n=12) over control (S: EMP last 
washing supernatant). However, higher amounts of EMP (≥ 2.105 EMP/well) had the reverse 
effect and progressively decreased the number of tubes to 50% at 8.105 EMP/well. Stars 
indicate significant changes (* p<0.05, ** p<0.01, *** p <0.001). Results are the mean±SD of 
twelve independent experiments.
 (B) Inverted light microscope (Olympus) representative 
images (400x magnification) showing EPDC tube formation in Matrigel in the absence and 
presence of 2.103 or 2.105 EMP per well. Stars indicate retracted cell clusters. (C) 
Experiments were performed in the presence of inhibitors of either plasmin formation (anti-
uPA antibody) or activity (α2-antiplasmin, α2-AP). The biphasic effect of EMP on tube 
formation (left bar panel) was abolished by the anti-uPA antibody (middle bar panel) and by 
α2-AP (right bar panel). Stars indicate significant changes (p<0.05). Results are the mean±SD 
of three independent experiments. 
 
Figure 5. EMP are involved in plasmin generation in Matrigel. (A) Plasmin generation in 
Matrigel is dependent on the amount of EMP. The chromogenic substrate CBS0065 was 
added to the Matrigel with the EMP and under these conditions an increase in plasmin 
formation was detected from 105 EMP (p<0.001) after 2 h of incubation. Stars indicate 
significant changes (p<0.05). Results are the mean±SD of three independent experiments. 
(B) Plasmin generation in Matrigel at different EMP amounts is dependant on the supply of 
plasminogen by FCS. The graph shows plasmin activity detected after 3 h of incubation (gray 
bar, medium with 10% FCS; black bar, medium with plasminogen-free FCS; hatched bar, 
medium with plasminogen-free FCS supplemented with 1 µM plasminogen). Activity in the 
absence of EMP may represent low levels of plasmin and/or limited amounts of activators in 
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Matrigel. Stars indicate significant changes (p<0.05). Results are the mean±SD of three 
independent experiments. 
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